Profile data is unavailable for this security.
About the company
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
- Revenue in USD (TTM)391.56m
- Net income in USD-76.58m
- Incorporated2013
- Employees979.00
- LocationTwist Bioscience Corp681 Gateway Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (800) 719-0671
- Fax+1 (302) 531-3150
- Websitehttps://www.twistbioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.10bn | 246.00 | 11.47 | 2.51 | 10.01 | 2.54 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Organon & Co | 6.30bn | 501.00m | 2.11bn | 10.00k | 4.21 | 2.32 | 2.50 | 0.3342 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 248.52m | -278.00k | 2.12bn | 188.00 | -- | 21.38 | 623.93 | 8.53 | -0.0055 | -0.0055 | 2.53 | 1.01 | 1.39 | 1.11 | 6.25 | 1,321,899.00 | -0.1554 | -42.00 | -0.2203 | -50.53 | 91.09 | -- | -0.1119 | -194.15 | 2.37 | -0.5126 | 0.2618 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| Ultragenyx Pharmaceutical Inc | 630.60m | -579.83m | 2.30bn | 1.29k | -- | 250.50 | -- | 3.64 | -5.94 | -5.94 | 6.46 | 0.095 | 0.4622 | 2.02 | 6.13 | 487,324.60 | -42.50 | -33.04 | -55.49 | -38.84 | 84.69 | 91.29 | -91.95 | -127.45 | 1.74 | -17.52 | 0.9809 | -- | 29.01 | 40.12 | 6.17 | -- | -4.24 | -- |
| Tarsus Pharmaceuticals Inc | 366.10m | -81.16m | 2.63bn | 323.00 | -- | 7.85 | -- | 7.19 | -2.01 | -2.01 | 8.99 | 7.89 | 0.8039 | 7.39 | 7.19 | 1,133,437.00 | -17.82 | -33.35 | -22.30 | -37.21 | 93.26 | -- | -22.17 | -125.04 | 4.25 | -- | 0.1774 | -- | 948.62 | -- | 14.97 | -- | 106.47 | -- |
| Supernus Pharmaceuticals Inc | 681.54m | -19.12m | 2.83bn | 674.00 | -- | 2.69 | 42.70 | 4.15 | -0.3408 | -0.3408 | 12.09 | 18.38 | 0.4934 | 0.959 | 4.30 | 1,011,185.00 | -1.38 | 4.25 | -1.79 | 5.58 | 89.91 | 87.90 | -2.80 | 10.41 | 1.56 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
| Apellis Pharmaceuticals Inc | 1.02bn | 44.99m | 2.85bn | 705.00 | 75.97 | 7.11 | 61.17 | 2.81 | 0.297 | 0.297 | 8.03 | 3.17 | 1.04 | 0.9298 | 3.25 | 1,441,698.00 | 4.59 | -61.31 | 6.04 | -76.53 | 88.85 | 86.49 | 4.43 | -157.26 | 3.10 | 2.51 | 0.5313 | -- | 97.02 | -- | 62.57 | -- | -24.96 | -- |
| Twist Bioscience Corp | 391.56m | -76.58m | 2.89bn | 979.00 | -- | 6.33 | -- | 7.38 | -1.27 | -1.27 | 6.46 | 7.44 | 0.6282 | 6.71 | 8.76 | 399,956.10 | -12.29 | -24.09 | -13.97 | -26.80 | 51.62 | 43.29 | -19.56 | -67.76 | 3.37 | -- | 0.00 | -- | 20.32 | 33.11 | 62.79 | -- | 23.20 | -- |
| Catalyst Pharmaceuticals Inc | 578.20m | 217.56m | 2.94bn | 181.00 | 13.95 | 3.20 | 11.51 | 5.08 | 1.71 | 1.71 | 4.55 | 7.47 | 0.6341 | 3.45 | 7.02 | 3,194,453.00 | 23.86 | 24.62 | 27.38 | 28.82 | 85.68 | 85.77 | 37.63 | 31.73 | 6.40 | -- | 0.00 | 0.00 | 23.49 | 36.89 | 129.50 | 38.75 | 95.70 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 200.84m | 3.15bn | 600.00 | 16.26 | 1.73 | 13.69 | 2.84 | 4.03 | 4.03 | 22.30 | 37.95 | 0.3286 | 3.09 | 6.13 | 1,850,798.00 | 5.94 | 4.13 | 6.16 | 4.30 | 56.10 | 56.31 | 18.09 | 13.13 | 2.51 | 8.11 | 0.3574 | 0.00 | 1.10 | 3.39 | 2.52 | 8.57 | -13.84 | -- |
| Arcutis Biotherapeutics Inc | 317.93m | -44.32m | 3.19bn | 342.00 | -- | 19.84 | -- | 10.04 | -0.3545 | -0.3545 | 2.49 | 1.31 | 0.7866 | 1.75 | 3.63 | 929,616.90 | -10.97 | -61.20 | -16.53 | -68.48 | 89.96 | -- | -13.94 | -406.29 | 3.28 | -2.61 | 0.407 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Kiniksa Pharmaceuticals Internationl PLC | 597.97m | 35.92m | 3.23bn | 315.00 | 94.96 | 6.00 | 86.28 | 5.40 | 0.4484 | 0.4484 | 7.81 | 7.10 | 0.9435 | 2.13 | 15.61 | 1,898,327.00 | 5.67 | -8.31 | 6.85 | -9.52 | 87.52 | -- | 6.01 | -17.33 | 3.51 | -- | 0.00 | -- | 56.60 | -- | -406.68 | -- | -38.71 | -- |
| Liquidia Corp | 69.22m | -121.85m | 3.62bn | 157.00 | -- | 163.62 | -- | 52.24 | -1.43 | -1.43 | 0.8101 | 0.2540 | 0.2618 | 0.6138 | 3.45 | 440,866.30 | -46.08 | -58.31 | -62.15 | -66.89 | 89.11 | 75.60 | -176.04 | -564.24 | 1.96 | -7.36 | 0.8972 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
Data as of Feb 06 2026. Currency figures normalised to Twist Bioscience Corp's reporting currency: US Dollar USD
66.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 30 Sep 2025 | 6.73m | 11.00% |
| Artisan Partners LPas of 30 Sep 2025 | 6.41m | 10.48% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.27m | 8.63% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.81m | 7.87% |
| William Blair Investment Management LLCas of 30 Sep 2025 | 4.14m | 6.77% |
| Edgepoint Investment Group, Inc.as of 30 Sep 2025 | 4.08m | 6.68% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 3.09m | 5.05% |
| Amova Asset Management Americas, Inc.as of 30 Sep 2025 | 2.12m | 3.47% |
| Amova Asset Management Co., Ltd.as of 31 Dec 2025 | 1.90m | 3.11% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2025 | 1.87m | 3.05% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
